Alster Stem Cells - Intramyocardial Stem Therapy

Percutaneous Intramyocardial Cell Therapy After Acute Myocardial Infarction Using Bone Marrow Mononuclear Cells

Study to assess the efficacy of intramyocardial bone marrow derived mononuclear cell therapy concerning left ventricular ejection fraction as measured by echocardiography.

Inclusion Criteria:

• LVDF < 45% after timely (max. 6 hours after the onset of symptomps) successful PCI
• conventional therapy according to the ESC guidelines for heart failure
• BMI > 20 and < 35

Exclusion Criteria:

• PCI elder then 21 days
• relevant valvular disease
• history of stroke/multivessel disease/thromboembolic event etc.
• DM Type I
• pregancy